Viking Therapeutics, Inc.
GB ˙ LSE ˙ US92686J1060
29,87 USD ↑0,55 (1,88%)
2026-06-04
CENA AKCJI
SecurityGB:0VQA / Viking Therapeutics, Inc.
InstitutionUBS Group AG
Latest Disclosed Ownership1,347,472 shares
Latest Disclosed Value $ 43,846,739
UBS Group AG ownership in 0VQA / Viking Therapeutics, Inc.

On May 5, 2026 - UBS Group AG filed a 13F-HR form disclosing ownership of 1,347,472 shares of Viking Therapeutics, Inc. (GB:0VQA) valued at $43,927,587 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 29, 2026 disclosing 934,925 shares of Viking Therapeutics, Inc.. This represents a change in shares of 44.13% during the quarter. The current value of the position is $40,248,989 USD.

UBS Group AG has a history of taking positions in derivatives of the underlying security (0VQA) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

GB:0VQA / Viking Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 1,347,472 412,547 44.13 43,847 33.31 0.0066
2026-01-29 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 934,925 -407,383 -30.35 32,891 -6.76 0.0053
2025-11-13 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 1,342,308 390,781 41.07 35,276 39.90 0.0055
2025-08-14 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 951,527 354,867 59.48 25,215 74.99 0.0044
2025-05-13 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 596,660 -21,488 -3.48 14,409 -42.07 0.0026
2025-02-14 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 618,148 289,189 87.91 24,874 19.44 0.0046
2024-11-14 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 328,959 -30,423 -8.47 20,826 9.32 0.0045
2024-08-14 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 359,382 85,326 31.13 19,051 -15.23 0.0047
2024-05-13 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 274,056 -65,670 -19.33 22,473 255.46 0.0056
2024-02-09 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 339,726 196,015 136.40 6,322 297.61 0.0019
2023-11-09 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 143,711 -13,347 -8.50 1,591 -37.52 0.0005
2023-08-11 2023-06-30 13F VIKING THERAPEUTICS COM 92686J106 157,058 -30,154 -16.11 2,546 -18.35 0.0009
2023-05-12 2023-03-31 13F VIKING THERAPEUTICS COM 92686J106 187,212 141,164 306.56 3,117 621.53 0.0011
2023-02-08 2022-12-31 13F VIKING THERAPEUTICS COM 92686J106 46,048 4,981 12.13 433 285.71 0.0002
2022-11-10 2022-09-30 13F VIKING THERAPEUTICS COM 92686J106 41,067 -1,238 -2.93 112 -8.20 0.0000
2022-08-10 2022-06-30 13F VIKING THERAPEUTICS COM 92686J106 42,305 -34,057 -44.60 122 -46.72 0.0001
2022-05-16 2022-03-31 13F VIKING THERAPEUTICS COM 92686J106 76,362 -255,799 -77.01 229 -85.01 0.0001
2022-02-14 2021-12-31 13F VIKING THERAPEUTICS COM 92686J106 332,161 61,347 22.65 1,528 -10.17 0.0004
2021-11-15 2021-09-30 13F VIKING THERAPEUTICS COM 92686J106 270,814 102,785 61.17 1,701 69.09 0.0005
2021-08-13 2021-06-30 13F VIKING THERAPEUTICS COM 92686J106 168,029 -137,565 -45.02 1,006 -47.93 0.0003
2021-05-12 2021-03-31 13F VIKING THERAPEUTICS COM 92686J106 305,594 220,695 259.95 1,932 304.18 0.0006
2021-02-11 2020-12-31 13F VIKING THERAPEUTICS COM 92686J106 84,899 -251,568 -74.77 478 -75.59 0.0002
2020-11-12 2020-09-30 13F VIKING THERAPEUTICS COM 92686J106 336,467 5,786 1.75 1,958 -17.90 0.0007
2020-07-31 2020-06-30 13F VIKING THERAPEUTICS COM 92686J106 330,681 -59,926 -15.34 2,385 30.47 0.0010
2020-05-01 2020-03-31 13F VIKING THERAPEUTICS COM 92686J106 390,607 -19,227 -4.69 1,828 -44.39 0.0009
2020-02-14 2019-12-31 13F VIKING THERAPEUTICS COM 92686J106 409,834 -169,656 -29.28 3,287 -17.56 0.0011
2019-11-14 2019-09-30 13F VIKING THERAPEUTICS COM 92686J106 579,490 15,332 2.72 3,987 -14.84 0.0015
2019-08-14 2019-06-30 13F VIKING THERAPEUTICS COM 92686J106 564,158 291,756 107.10 4,682 72.90 0.0018
2019-05-14 2019-03-31 13F VIKING THERAPEUTICS COM 92686J106 272,402 -236,570 -46.48 2,708 -30.46 0.0011
2019-02-14 2018-12-31 13F VIKING THERAPEUTICS COM 92686J106 508,972 302,815 146.89 3,894 8.44 0.0018
2018-11-14 2018-09-30 13F VIKING THERAPEUTICS COM 92686J106 206,157 123,956 150.80 3,591 360.38 0.0014
2018-08-14 2018-06-30 13F VIKING THERAPEUTICS COM 92686J106 82,201 18,872 29.80 780 181.59 0.0003
2018-05-15 2018-03-31 13F VIKING THERAPEUTICS COM 92686J106 63,329 53,329 533.29 277 575.61 0.0001
2018-02-14 2017-12-31 13F VIKING THERAPEUTICS COM 92686J106 10,000 10,000 41 0.0000
2017-11-14 2017-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 0 -4,506 -100.00 0 -100.00
2017-11-14 2017-03-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 4,506 4,506 7 0.0000
2017-05-12 2017-03-31 13F VIKING THERAPEUTICS COM 92686J106 4,506 4,506 7
2016-11-14 2016-09-30 13F VIKING THERAPEUTICS COM 92686J106 0 -3,252 -100.00 0 -100.00
2016-08-12 2016-06-30 13F VIKING THERAPEUTICS COM 92686J106 3,252 767 30.87 4 0.00 0.0000
2016-05-12 2016-03-31 13F VIKING THERAPEUTICS COM 92686J106 2,485 2,485 0.00 4 0.0000
2016-02-16 2015-12-31 13F VIKING THERAPEUTICS COM 92686J106 0 -1,408 -100.00 0 -100.00
2015-11-13 2015-09-30 13F VIKING THERAPEUTICS COM 92686J106 1,408 1,408 8 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-05 2026-03-31 13F VIKING THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-01-29 2025-12-31 13F VIKING THERAPEUTICS COM Call 39,800 -43.14 1,400 -23.87 n/a n/a n/a
2025-11-13 2025-09-30 13F VIKING THERAPEUTICS COM Call 70,000 1,840 n/a n/a n/a
2024-11-14 2024-09-30 13F VIKING THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F VIKING THERAPEUTICS COM Call 26,500 1,405 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-07-31 2020-06-30 13F VIKING THERAPEUTICS COM Put 0 -100.00 0 n/a n/a n/a
2020-05-01 2020-03-31 13F VIKING THERAPEUTICS COM Put 100 0 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.